Compare Gilead Sciences, Inc. (GILD) vs Solaredge Technologies Inc (SEDG) Price & Performance

Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.

Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.

SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $405.45 million in 2025, with a negative net margin of -34.24%, though revenue improved to $1.18 billion. Recent news highlights an ongoing fraud investigation by Pomerantz Law Firm and ambitious long-term revenue targets of $2.4 billion by 2029, alongside new AI data center initiatives developed with NVIDIA.

The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests modest upside with a $37.75 price target. Key risks include execution on growth targets, competitive pressures, and macroeconomic headwinds affecting solar project financing. Institutional sentiment is cautious, with 56.25% hold ratings.